https://pubmed.ncbi.nlm.nih.gov/38114198

The abstract reports the findings of a post hoc analysis of the MUST trial, which suggest that female and male psoriatic arthritis patients may have differences in treatment responses and adverse events during IL-12/23 therapy with or without methotrexate.